Navigation Links
NuVasive to Present at William Blair 28th Annual Growth Stock Conference
Date:6/9/2008

SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Executive Vice President and Chief Financial Officer is scheduled to present at the William Blair 28th Annual Growth Stock Conference at the Four Season Hotel, Chicago, IL, on Wednesday, June 18, 2008, at 8:30 a.m. CT.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact: Investors:

Kevin C. O'Boyle Nick Laudico/Zack Kubow

EVP & Chief Financial Officer The Ruth Group

NuVasive, Inc. 646-536-7030/7020

858-909-1800 nlaudico@theruthgroup.com

investorrelations@nuvasive.com zkubow@theruthgroup.com

Media:

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
2. NuVasive to Host Investor Reception on September 11, 2007
3. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
4. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
6. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Avicena Group to Present at Noble Financial Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency Miami, January ... discussions to examine vital clinical research issues such as trial performance metrics, patient ...
(Date:1/18/2017)... 18, 2017 Shareholder rights law firm Johnson ... the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... with the proposed sale of the Company to Eli ... develops small molecules for the acute treatment of migraines. ... had signed a definitive merger agreement with Eli Lilly. ...
(Date:1/18/2017)... , Jan. 18, 2017  Market Research Future published a ... Market is expected to grow at a CAGR of 12% during ... ... caused due to the abnormal cell division without any control. These ... harm to them. These cancer cells can spread to other parts ...
(Date:1/17/2017)...  An international team of researchers from UC ... Hospital Albrechtsen Research Centre/University of Manitoba have identified ... need affecting nearly one in 15 Americans. Published ... results identify small molecule drugs with neuroprotective and ... in animal models of metabolic, chemical and infection ...
Breaking Biology Technology:
(Date:12/15/2016)... 15, 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow ... The report has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
(Date:12/8/2016)... 2016 Market Research Future published a half cooked research ... Biometric Security and Service Market is expected to grow over the ... Market Highlights: ... Mobile Biometric Security and Service Market ... need of authentication and security from unwanted cyber threats. The increasing ...
(Date:12/7/2016)... , Dec. 7, 2016   Veridium , ... the appointment of new CEO James Stickland ... with decades of experience, has served in senior ... where he specialized in expanding a pipeline of ... portfolios. He most recently served as managing director ...
Breaking Biology News(10 mins):